| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3948694 | Gynecologic Oncology Case Reports | 2013 | 4 Pages |
Abstract
► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Han Hsi Wong, Christine Parkinson, Jonathan A. Ledermann, James D. Brenton, Michael Merger, Ashley Shaw, Aileen Patterson, Mahmood Shafi, Helena M. Earl,